Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025
Akoya Biosciences (NASDAQ: AKYA) has announced two major developments in its spatial biology portfolio. First, the company launched a new multiplex immunofluorescence (mIF) assay for antibody-drug conjugate (ADC) development in breast cancer, now available through Advanced Biopharma Services (ABS). The panel includes HER2, TROP2, Ki-67, ER/PR, and a membrane-localization cocktail, enabling precise patient selection and quantification of ADC targets.
The assay is optimized for identifying HER2-low and TROP2-high patients in clinical trials and features comprehensive support from a CLIA-certified laboratory. Additionally, Akoya will showcase customer-generated real-world data from their PhenoCode™ Discovery IO60 panel at the AACR 2025 Annual Meeting (April 25-30, Chicago), demonstrating its capabilities in immune phenotyping and tumor microenvironment profiling.
Akoya Biosciences (NASDAQ: AKYA) ha annunciato due importanti novità nel suo portafoglio di biologia spaziale. Innanzitutto, l'azienda ha lanciato un nuovo test multiplex di immunofluorescenza (mIF) per lo sviluppo di coniugati anticorpo-farmaco (ADC) nel carcinoma mammario, ora disponibile tramite Advanced Biopharma Services (ABS). Il pannello include HER2, TROP2, Ki-67, ER/PR e un cocktail per la localizzazione di membrana, permettendo una selezione precisa dei pazienti e la quantificazione dei target ADC.
Il test è ottimizzato per identificare pazienti HER2-low e TROP2-high negli studi clinici e offre un supporto completo da un laboratorio certificato CLIA. Inoltre, Akoya presenterà dati reali generati dai clienti con il pannello PhenoCode™ Discovery IO60 durante il AACR 2025 Annual Meeting (25-30 aprile, Chicago), dimostrando le sue capacità nel fenotipaggio immunitario e nel profiling del microambiente tumorale.
Akoya Biosciences (NASDAQ: AKYA) ha anunciado dos importantes avances en su portafolio de biología espacial. Primero, la compañía lanzó un nuevo ensayo multiplex de inmunofluorescencia (mIF) para el desarrollo de conjugados anticuerpo-fármaco (ADC) en cáncer de mama, ahora disponible a través de Advanced Biopharma Services (ABS). El panel incluye HER2, TROP2, Ki-67, ER/PR y un cóctel de localización de membrana, permitiendo una selección precisa de pacientes y la cuantificación de los objetivos ADC.
El ensayo está optimizado para identificar pacientes HER2-low y TROP2-high en ensayos clínicos y cuenta con soporte integral de un laboratorio certificado CLIA. Además, Akoya presentará datos del mundo real generados por clientes con el panel PhenoCode™ Discovery IO60 en el AACR 2025 Annual Meeting (25-30 de abril, Chicago), demostrando sus capacidades en fenotipificación inmune y perfilado del microambiente tumoral.
Akoya Biosciences (NASDAQ: AKYA)가 공간 생물학 포트폴리오에서 두 가지 주요 발전을 발표했습니다. 먼저, 회사는 유방암 항체-약물 접합체(ADC) 개발을 위한 새로운 다중면역형광(mIF) 분석법을 출시했으며, 이는 현재 Advanced Biopharma Services(ABS)를 통해 제공됩니다. 이 패널에는 HER2, TROP2, Ki-67, ER/PR 및 막 위치화 칵테일이 포함되어 있어 정확한 환자 선별과 ADC 타깃의 정량화가 가능합니다.
이 분석법은 임상 시험에서 HER2-low 및 TROP2-high 환자 식별에 최적화되어 있으며, CLIA 인증 실험실의 포괄적인 지원을 받습니다. 또한 Akoya는 AACR 2025 연례회의(4월 25-30일, 시카고)에서 PhenoCode™ Discovery IO60 패널을 활용한 고객 생성 실제 데이터를 선보이며 면역 표현형 분석 및 종양 미세환경 프로파일링 능력을 입증할 예정입니다.
Akoya Biosciences (NASDAQ : AKYA) a annoncé deux avancées majeures dans son portefeuille de biologie spatiale. Tout d'abord, la société a lancé un nouveau test multiplex d'immunofluorescence (mIF) pour le développement de conjugués anticorps-médicament (ADC) dans le cancer du sein, désormais disponible via Advanced Biopharma Services (ABS). Le panel comprend HER2, TROP2, Ki-67, ER/PR ainsi qu'un cocktail de localisation membranaire, permettant une sélection précise des patients et la quantification des cibles ADC.
Le test est optimisé pour identifier les patients HER2-low et TROP2-high lors des essais cliniques et bénéficie d'un support complet d'un laboratoire certifié CLIA. De plus, Akoya présentera des données réelles générées par ses clients avec le panel PhenoCode™ Discovery IO60 lors du AACR 2025 Annual Meeting (25-30 avril, Chicago), démontrant ses capacités en phénotypage immunitaire et en profilage du microenvironnement tumoral.
Akoya Biosciences (NASDAQ: AKYA) hat zwei bedeutende Entwicklungen in seinem Portfolio der räumlichen Biologie bekannt gegeben. Zunächst hat das Unternehmen einen neuen multiplex Immunfluoreszenz (mIF) Test für die Entwicklung von Antikörper-Wirkstoff-Konjugaten (ADC) bei Brustkrebs eingeführt, der nun über Advanced Biopharma Services (ABS) verfügbar ist. Das Panel umfasst HER2, TROP2, Ki-67, ER/PR sowie einen Membranlokalisierungs-Cocktail und ermöglicht eine präzise Patientenauswahl sowie die Quantifizierung von ADC-Zielen.
Der Test ist darauf optimiert, HER2-low und TROP2-high Patienten in klinischen Studien zu identifizieren und wird von einem CLIA-zertifizierten Labor umfassend unterstützt. Darüber hinaus wird Akoya auf dem AACR 2025 Annual Meeting (25.-30. April, Chicago) kundengenerierte Real-World-Daten aus dem PhenoCode™ Discovery IO60 Panel präsentieren und damit seine Fähigkeiten in der Immun-Phänotypisierung und Tumormikroumgebungsprofilierung demonstrieren.
- Launch of new ADC breast cancer assay expanding biopharma service portfolio
- CLIA-certified laboratory capabilities for clinical-grade assay development
- Customer validation of IO60 panel demonstrating real-world effectiveness
- None.
Insights
Akoya expands services with ADC breast cancer assay, strengthening its position in the growing spatial biology market for precision oncology.
Akoya's newly launched ADC breast cancer assay represents a strategic addition to their Advanced Biopharma Services (ABS) portfolio. The assay targets a significant clinical need in the rapidly evolving ADC therapeutic landscape, where drugs targeting HER2 and TROP2 (mentioned in the DESTINY, ASCENT, and TROPiCS trials) are changing treatment paradigms.
The multiplex immunofluorescence panel delivers key capabilities that address pharmaceutical research challenges: normalized protein expression quantification, membrane/cytoplasmic expression ratio measurement, and comparative analysis with standard biomarkers. These features directly support more precise patient selection for clinical trials - a critical factor in ADC development.
By integrating this assay into their CLIA-certified laboratory services, Akoya is strengthening their end-to-end offering that spans from assay customization through analysis and reporting. This positions them not just as a technology provider but as a comprehensive research partner for biopharma companies developing ADC therapies.
The customer presentation featuring real-world data from their IO60 panel provides valuable validation of their platform's practical utility. As noted by CEO Brian McKelligon, this customer adoption demonstrates the translation of their technology into actionable research insights - a critical milestone for any life science tools company.
The company's strategic emphasis on translational applications is evident in their AACR presence, which highlights the connection between discovery research and clinical applications. This positions Akoya to potentially capture value across the entire therapeutic development workflow.
Akoya's new ADC assay enables precise subcellular localization of targets critical for breast cancer treatment selection and development.
The new ADC-focused assay addresses a sophisticated technical challenge in breast cancer precision medicine: simultaneously quantifying multiple biomarkers with subcellular localization precision. For ADC therapeutics, the membrane versus cytoplasmic expression ratio is particularly critical, as these drugs require surface target expression for effective delivery of their cytotoxic payloads.
The panel's specific markers (HER2, TROP2, Ki-67, ER/PR) are strategically selected to integrate with established breast cancer classification systems while adding the dimensional precision needed for ADC development. This allows researchers to identify important patient subpopulations like HER2-low and TROP2-high individuals who might benefit from targeted therapies.
The proprietary membrane-localization cocktail mentioned suggests technical innovation in distinguishing subcellular compartments - a capability that exceeds standard immunohistochemistry approaches. This spatial resolution at the subcellular level supports more nuanced therapeutic decision-making beyond simple positive/negative classifications.
The real-world validation of their PhenoCode Discovery IO60 panel for deep immune phenotyping and tumor microenvironment profiling demonstrates the platform's practical utility in complex research settings. With 60 markers simultaneously analyzed, researchers can explore immune cell distributions and interactions within the tumor context at unprecedented depth.
From a translational research perspective, these technologies bridge the gap between discovery and clinical application, potentially accelerating biomarker identification for patient stratification strategies. The integration of these tools into Akoya's biopharma services offers a pathway for moving from biological insights to clinical implementation.
ADC assay now available through ABS; customer study proves IO60 is a spatial workhorse
MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, today announced the availability of a new assay designed to advance antibody-drug conjugate (ADC) development in breast cancer. The new assay will be featured alongside customer-generated real-world data from the PhenoCode™ Discovery IO60 panel—Akoya’s flagship ultrahigh-plex immuno-oncology solution—at the American Association for Cancer Research (AACR) 2025 Annual Meeting, taking place April 25–30 in Chicago, Illinois.
New ADC Assay: Advancing Breast Cancer Precision
The emergence of HER2- and TROP2-targeting ADCs—such as those used in the DESTINY, ASCENT, and TROPiCS trials—have transformed breast cancer treatment while introducing greater complexity in therapeutic decision-making. Akoya’s newly launched multiplex immunofluorescence (mIF) panel is designed to address these challenges by enabling more precise patient selection within established breast cancer subtypes.
This ADC-focused panel includes HER2, TROP2, Ki-67, ER/PR, and a proprietary membrane-localization cocktail. It allows for simultaneous quantification of ADC target expression with precise subcellular localization, providing:
- Normalized protein expression
- Membrane/cytoplasmic expression ratios
- Comparative analysis with standard-of-care IHC biomarkers
Now available through Akoya’s Advanced Biopharma Services (ABS), the ADC panel includes comprehensive support—from assay customization to tissue staining, high-resolution imaging, image analysis, and reporting. ABS is purpose-built to accelerate the path from translational discovery to IUO and IVD, with capabilities anchored in:
- A CLIA-certified laboratory for clinical-grade assay development
- Integrated imaging and analysis workflows for multiplexed biomarker quantification
- A clinical trial site and global CRO network for end-to-end study support
The panel is optimized for:
- Identifying HER2-low and TROP2-high patients in clinical trial cohorts
- Resolving membrane versus cytoplasmic marker expression—critical for ADC efficacy
- Delivering consistent, quantitative scoring of each ADC marker
“Multiplexing key targets in context with state-of-the-art membrane resolution is a catalyst for designing precise ADC combination strategies,” said Pascal Bamford, Chief Clinical Officer at Akoya. “Our goal is to equip translational and clinical teams with assays that reflect the complexity of the tumor microenvironment while preserving clinical relevance.”
Real-World Impact of IO60: Proven in the Field
Originally launched at SITC 2024, the PhenoCode Discovery IO60 panel remains the fastest ultrahigh-plex spatial proteomics solution for immuno-oncology research. At AACR 2025, one of Akoya’s customers will present real-world data generated using IO60, showcasing its power in:
- Deep immune phenotyping
- Tumor microenvironment (TME) profiling
- Translating biomarker discovery across oncology pipelines
“Seeing our partners generate impactful insights using IO60 is the strongest validation of our platform’s potential,” said Brian McKelligon, Chief Executive Officer of Akoya. “This is how spatial biology becomes translational—by helping researchers get closer to patient-relevant outcomes.”
Visit Akoya at AACR 2025 – Booth #3045
Both innovations—the ADC-focused breast cancer panel and customer-generated data using IO60—will be featured at Booth #3045, where Akoya will highlight the full potential of spatial biology in translational research. Visit us to explore the PhenoCode panel portfolio, meet with our scientific team, and experience our latest innovations firsthand.
What to Look Forward To:
- Live Atlas Demo with Enable Medicine – Translating spatial data into actionable insights: April 27 | 4:30–5:00 PM | Akoya Booth #3045
- Spotlight Theatre Presentation: From Discovery to Translation: Scaling Spatial Biology for Oncology Breakthroughs: April 28 | 3:00–4:00 PM | Spotlight Theater A – South Hall A
- CDx Strategy Discussion with Clinical Experts: April 28 | 4:15–5:00 PM | Akoya Booth #3045
- Early access opportunities to Akoya’s newest translational panels and biopharma service offerings
For more information about Akoya’s AACR 2025 presence, visit: https://sb.akoyabio.com/aacr2025.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding the potential of our products and services, statements regarding the potential of spatial biology in translational research, and other statements regarding our business strategies and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
Investor Contact:
Priyam Shah
investors@akoyabio.com
Media Contact:
Ritu Mihani
media@akoyabio.com
FAQ
What is the new ADC breast cancer assay launched by Akoya Biosciences (AKYA)?
How does Akoya's (AKYA) new ADC assay benefit breast cancer research?
What capabilities does Akoya's (AKYA) Advanced Biopharma Services offer for the new ADC panel?
What will Akoya Biosciences (AKYA) present at AACR 2025?
